title: Subconjunctival bevacizumab for corneal neovascularization.
abstract: OBJECTIVE
  To report the efficacy of subconjunctival bevacizumab injection in patients with corneal neovascularization (NV).
  
  
  METHODS
  This retrospective interventional case study included two eyes of two patients with corneal NV due to aqueous-deficient dry eye with filamentary keratitis in the first case, and corneal graft failure in the second case. Patients received a subconjunctival injection of 2.5 mg (0.1 ml) bevacizumab. Morphologic changes were investigated by slit-lamp biomicroscopy and corneal photography.
  
  
  RESULTS
  Corneal NV was dramatically regressed a week after injection in the first case. In the second case, minor vessels were regressed while the major one did not. No infection or inflammation was observed. No relapse was seen within the follow-up of two to three months.
  
  
  CONCLUSIONS
  Subconjunctival injection of bevacizumab may offer an additional strategy for the treatment of corneal NV.
authors: Department of Ophthalmology, Fatih University Medical School, Alparslan Turkes Cad No: 57, 06510 Emek, Ankara, Turkey. merdurmus@yahoo.com
authors: Mesut
authors: M
authors: Erdurmus
authors: Yuksel
authors: Y
authors: Totan
mesh_terms: D000328:Adult; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003228:Conjunctiva; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007267:Injections; D008297:Male; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab